Cost-effectiveness models of pneumococcal conjugate vaccines: Variability and impact of modeling assumptions

Raymond A Farkouh*, Rogier M Klok, Maarten J Postma, Craig S Roberts, David R Strutton

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)

Abstract

Currently, 13-valent pneumococcal conjugate vaccine (PCV); and ten-valent PCV vaccine are marketed. Neither vaccine obtained regulatory approval based on efficacy trials, but instead were approved based on a surrogate end point: immunogenicity data measuring effective antibody levels. Therefore, direct measures of efficacy were unavailable at the time economic analyses were conducted. The authors systematically reviewed cost-effectiveness studies of ten-valent PCV and 13-valent PCV from the literature to analyze the methodologies and compare the assumptions made about vaccine effectiveness. The following three inputs were found the most variant across analyses: efficacy against acute otitis media; inclusion of indirect effects; and cross protection. These assumptions are discussed with regard to the validity of supporting data and implications on decision-making.

Original languageEnglish
Pages (from-to)1235-1247
Number of pages13
JournalExpert review of vaccines
Volume11
Issue number10
DOIs
Publication statusPublished - Oct-2012

Keywords

  • acute otitis media
  • cost-effectiveness analysis
  • cross protection
  • herd effects
  • invasive pneumococcal disease
  • nontypable Haemophilus influenzae
  • PCV7
  • PCV10
  • PCV13
  • PHiD-CV
  • pneumococcal conjugate vaccine
  • pneumonia
  • ACUTE OTITIS-MEDIA
  • NONTYPABLE HAEMOPHILUS-INFLUENZAE
  • STREPTOCOCCUS-PNEUMONIAE
  • NASOPHARYNGEAL CARRIAGE
  • ECONOMIC-EVALUATION
  • UNITED-STATES
  • PROTEIN-D
  • PHID-CV
  • UNIVERSAL IMMUNIZATION
  • INFANT VACCINATION

Cite this